Fresh frozen plasma as a complement source

Lancet Oncology

Volumn 8, Issue 5, 2007, Pages 370-371

  Taylor, Ronald ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENT; FRESH FROZEN PLASMA; RITUXIMAB;

B LYMPHOCYTE; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEFICIENCY; COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; COMPLEMENT SYSTEM PROTEINS; DRUG SYNERGISM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MIDDLE AGED; PLASMA; TREATMENT OUTCOME;

EID: 34247192685     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70114-6     Document Type: Letter

References (6)

1. Klepfish A., Schattner A., Ghoti H., and Rachmilewitz E. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol 8 (2007) 361-362
2. Kennedy A., Beum P., Solga M., et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172 (2004) 3280-3288
3. Golay J., Zaffaroni L., Vaccari T., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 95 (2000) 3900-3908
4. Kennedy A., Solga M., Schuman T., et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by Rituximab. Blood 101 (2003) 1071-1079
5. Cragg M., Walshe C., Ivanov A., et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8 (2005) 140-174
6. Williams M., Densmore J., Pawluczkowycz A., et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 177 (2006) 7435-7443